drugset / Trial / NCT07613567
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy and safety of "neoadjuvant immunotherapy combined with chemotherapy followed by immunotherapy combined with radiotherapy during the radiotherapy period" versus "standard concurrent chemoradiotherapy" in locally advanced cervical cancer.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2032-08-31
- Completion
- 2032-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | 90 mg/m2 | — |
| Subject | Carboplatin | Small molecule | 1.5 unknown | — |
| Comparator | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Comparator | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | — |